Short answer
GERON CORP (GERN) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $47M (up 67.1% year over year) with net income of −$18M.
Q3 2025 key financials · XBRL
- Revenue
- $47M
- +67.1% YoY · −3.7% QoQ
- Net income
- −$18M
- +30.3% YoY · −12.5% QoQ
- Operating margin
- -29.4%
- EPS (diluted)
- −$0.03
- +25.0% YoY · −50.0% QoQ
Source: XBRL data from the GERON CORP (GERN) Q3 2025 10-Q on SEC EDGAR. USD.
GERON CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New FDA approval June 2024 for RYTELO in U.S. lower-risk MDS triggers reliance risk on single product commercialization
- Most material update: Increased U.S. sales force by 20%, medical affairs team by 100% to support RYTELO commercialization amid variable quarterly revenues ($39.4M to $49.0M)
- Regulatory risk: Post-marketing commitments for RYTELO with risk of penalties or withdrawal if non-compliant or adverse events occur
- Operational risk: Dependence on third-party distributors/specialty pharmacies for U.S. RYTELO distribution with limited experience in international commercialization
- Financial risk: Need for additional capital to fund commercialization efforts; failure to obtain may halt RYTELO development and commercialization leading to severe adverse effects
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GERON CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.